Menu Expand
  1. Subjects (Books)
Treatment of Skin Disease E-Book

BOOK

Treatment of Skin Disease E-Book

Mark G. Lebwohl | Warren R. Heymann | John Berth-Jones | Ian Coulson

(2017)

Login to order (PDF)

Additional Information

Book Details

ISBN
978-0-7020-6913-0
Edition
5
Language
English
Pages
912
Subjects
General practice
Dermatology
Medical microbiology & virology

Abstract

Covering more than 250 of the most common dermatologic conditions from A to Z, Treatment of Skin Disease, 5th Edition, by Drs. Mark G. Lebwohl, Warren R. Heymann, John Berth-Jones, and Ian Coulson, is your go-to resource for authoritative, evidence-based treatment strategies in your daily practice. This award-winning text provides guidance on the fast-moving dermatological therapy options for virtually any skin disease you’re likely to encounter, including third-line and unusual therapies when initial options have not been successful. Summaries of each treatment strategy are accompanied by detailed discussions of treatment choices, with ratings on a consistent scale ranging from clinical studies to anecdotal reports.

  • Puts every possible therapeutic option at your disposal – including management strategies and first- to third-line therapies – for a truly complete guide to the vast array of dermatologic treatment options.

  • Presents information in a consistent, tabular format, with checklists of diagnostic and investigative pearls and color-coded boxes for quick reference.
  • Offers the combined knowledge and expertise of the world’s leading authorities in dermatology.
  • Features eight all-new chapters on Atypical Fibroxanthoma, Confluent and Reticulated Papillomatosis, Cryopyrin Associated Periodic Syndromes (CAPS), Hypopigmented Dermatoses, Nail Psoriasis, Necrolytic Acral Erythema, Post-inflammatory Hyperpigmentation, and Regional Pain.

  • Provides more than 250 full-color clinical images of skin diseases, most of which are new to this edition.

  • Includes off-label uses, new treatments like therapeutic antibodies and hedgehog inhibitors, and new indications for existing treatments.

Table of Contents

Section Title Page Action Price
Front Cover Cover
Treatment of Skin Disease: Comprehensive Therapeutic Strategies i
Treatment of Skin Disease: Comprehensive Therapeutic Strategies iii
Copyright iv
Contents v
Preface xi
List of Contributors xiii
Acknowledgments xxv
Dedication xxvi
Evidence Levels xxvii
Credits xxviii
PHOTOS xxviii
TABLES xxviii
BOXES xxviii
1 - Acanthosis nigricans 1
MANAGEMENT STRATEGY 1
2 - Acne keloidalis nuchae 4
MANAGEMENT STRATEGY 4
Acknowledgment 5
3 - Acne vulgaris 6
MANAGEMENT STRATEGY 6
4 - Acrodermatitis enteropathica 12
MANAGEMENT STRATEGY 12
Acknowledgment 13
5 - Actinic keratoses 14
MANAGEMENT STRATEGY 14
6 - Actinic prurigo: (Synonyms: hereditary polymorphic light eruption of American Indians, Hutchinson summer prurigo, photodermatitis in North American Indians) 18
MANAGEMENT STRATEGY 18
7 - Actinomycosis 21
MANAGEMENT STRATEGY 21
8 - Acute generalized exanthematous pustulosis 24
MANAGEMENT STRATEGY 24
9 - Allergic contact dermatitis and photoallergy 26
MANAGEMENT STRATEGY 26
10 - Alopecia areata 29
MANAGEMENT STRATEGY 29
11 - Amyloidosis 34
MANAGEMENT STRATEGY 34
12 - Androgenetic alopecia 37
MANAGEMENT STRATEGY 37
13 - Angiolymphoid hyperplasia with eosinophilia 41
MANAGEMENT STRATEGY 41
14 - Angular cheilitis 44
MANAGEMENT STRATEGY 44
15 - Antiphospholipid syndrome 46
MANAGEMENT STRATEGY 46
16 - Aphthous stomatitis 49
MANAGEMENT STRATEGY 49
17 - Atopic dermatitis 54
MANAGEMENT STRATEGY 54
Interventional education 54
Skin care 54
Topical therapies 55
Other treatment considerations 55
Systemic therapies 56
Referral, quality of life issues, and educational resources 57
Hospitalization 57
18 - Atypical fibroxanthoma 63
MANAGEMENT STRATEGY 63
19 - Atypical nevi 66
MANAGEMENT STRATEGY 67
SPECIFIC INVESTIGATIONS 67
FIRST-LINE THERAPIES 68
20 - Autoimmune progesterone dermatitis 70
MANAGEMENT STRATEGY 70
21 - Bacillary angiomatosis 73
MANAGEMENT STRATEGY 73
22 - Balanitis 76
MANAGEMENT STRATEGY 76
23 - Basal cell carcinoma 79
MANAGEMENT STRATEGY 79
24 - Becker nevus 84
MANAGEMENT STRATEGY 84
25 - Bed bugs 87
MANAGEMENT STRATEGY 87
Visual inspection 88
Canine inspection 88
Bed bug traps 88
Other monitoring devices 88
Skin biopsy 89
26 - Behçet disease 90
MANAGEMENT STRATEGY 90
27 - Bioterrorism 94
SMALLPOX 94
MANAGEMENT STRATEGY 94
ANTHRAX 96
MANAGEMENT STRATEGY 97
TULAREMIA 98
MANAGEMENT STRATEGY 98
PLAGUE 99
MANAGEMENT STRATEGY 99
VIRAL HEMORRHAGIC FEVERS 100
MANAGEMENT STRATEGY 100
28 - Bites and stings 102
MANAGEMENT STRATEGY 102
Bite reactions 102
Anaphylaxis 102
Vectorborne disease 102
29 - Blastomycosis 105
MANAGEMENT STRATEGY 105
GUIDELINES 107
30 - Blistering distal dactylitis 108
MANAGEMENT STRATEGY 108
31 - Body dysmorphic disorder (dermatologic nondisease): Synonyms: Dermatologic nondisease, Body dysmorphic disease, Dysmorphophobia 110
MANAGEMENT STRATEGY 110
Hallmarks and Flags for Diagnosis of Body Dysmorphic Disorder 110
Diagnostic Aids 112
32 - Bowen disease and erythroplasia of Queyrat 114
DIAGNOSIS 114
MANAGEMENT STRATEGY 114
33 - Bullous pemphigoid 116
MANAGEMENT STRATEGY 116
34 - Burning mouth syndrome (glossodynia) 120
MANAGEMENT STRATEGY 120
Local factors 120
Systemic factors 120
Psychological factors 120
SPECIFIC INVESTIGATIONS 120
35 - Calcinosis cutis 124
MANAGEMENT STRATEGY 124
36 - Calciphylaxis 128
MANAGEMENT STRATEGY 128
37 - Capillaritis (pigmented purpuric dermatoses) 131
MANAGEMENT STRATEGY 131
38 - Cat scratch disease 134
MANAGEMENT STRATEGY 134
Immunocompetent individuals 135
39 - Cellulite 136
MANAGEMENT STRATEGY 136
40 - Cellulitis and erysipelas 139
MANAGEMENT STRATEGY 139
41 - Chancroid 143
DIAGNOSIS AND MANAGEMENT STRATEGY 143
SPECIAL CONSIDERATIONS: EVACUATION OF BUBOES AND UNUSUAL MANIFESTATIONS 144
42 - Chilblains 145
MANAGEMENT STRATEGY 145
43 - Chondrodermatitis nodularis helicis chronicus 147
MANAGEMENT STRATEGY 147
44 - Chromoblastomycosis 150
MANAGEMENT STRATEGY 150
45 - Chronic actinic dermatitis 154
MANAGEMENT STRATEGY 154
46 - Coccidioidomycosis 158
MANAGEMENT STRATEGY 158
CURRENT GUIDELINES 160
47 - Confluent and reticulated papillomatosis 161
MANAGEMENT STRATEGY 161
48 - Cryopyrin-associated periodic syndromes (CAPS) 165
MANAGEMENT STRATEGY 165
SECOND-LINE THERAPY 167
49 - Cryptococcosis 168
MANAGEMENT STRATEGY 168
GUIDELINES 170
50 - Cutaneous candidiasis and chronic mucocutaneous candidiasis 171
Cutaneous candidiasis 171
MANAGEMENT STRATEGY 171
CHRONIC MUCOCUTANEOUS CANDIDIASIS 172
MANAGEMENT STRATEGY 172
51 - Cutaneous larva migrans 175
MANAGEMENT STRATEGY 175
SPECIFIC INVESTIGATIONS 175
52 - Cutaneous polyarteritis nodosa 177
MANAGEMENT STRATEGY 177
53 - Darier disease 179
MANAGEMENT STRATEGY 179
54 - Decubitus ulcers 181
MANAGEMENT STRATEGY 181
Prevention 181
Management 181
Removal of Necrotic Debris 181
Maintenance of a Moist Wound Environment 182
Correction of the Underlying Contributing Factors 182
General Measures 182
Blanchable Erythema and Nonblanchable Erythema 182
Decubitus Dermatitis 182
Superficial and Deep Ulcers 182
Underlying Contributing Factors 182
Categories of Patients 183
Grading or Evaluation 183
Dermatologic Observation 183
Staging 183
Pathophysiology 183
Pathophysiology of acute wound healing. Li J, Chen J, Kirsner R. Clin Dermatol 2007; 25: 9–18 183
Histology 183
Risk Assessment Tools 183
Factors Predicting Pressure Ulcers 183
Treatment 184
Eliminating Pressure and Relieving Devices 184
Palliative Care 184
Debridement 184
Cleansing 185
Antimicrobial Agents 185
Nutrition 185
Synthetic Dressing 185
55 - Delusions of parasitosis 187
MANAGEMENT STRATEGY 187
56 - Dermatitis artefacta 190
MANAGEMENT STRATEGY 190
Factitious Dermatitis 191
57 - Dermatitis herpetiformis 192
MANAGEMENT STRATEGY 192
58 - Dermatofibrosarcoma protuberans 195
MANAGEMENT STRATEGY 195
59 - Dermatomyositis 198
MANAGEMENT STRATEGY 198
Treatment 198
60 - Diaper dermatitis 203
MANAGEMENT STRATEGY 203
61 - Discoid (Nummular) eczema 206
MANAGEMENT STRATEGY 206
62 - Discoid lupus erythematosus 209
MANAGEMENT STRATEGY 209
63 - Dissecting cellulitis of the scalp 211
MANAGEMENT STRATEGY 211
64 - Drug eruptions 213
MANAGEMENT STRATEGY 213
Differential diagnosis 213
Drug exposure (timing) 213
Determine probabilities 213
65 - Eosinophilic fasciitis 216
MANAGEMENT STRATEGY 216
66 - Epidermal nevi 220
MANAGEMENT STRATEGY 220
VERRUCOUS EPIDERMAL NEVI 221
INFLAMMATORY/DYSPLASTIC EPIDERMAL NEVI 222
67 - Epidermodysplasia verruciformis 224
MANAGEMENT STRATEGY 224
68 - Epidermolysis bullosa 226
MANAGEMENT STRATEGY 226
69 - Epidermolysis bullosa acquisita 229
MANAGEMENT STRATEGY 229
70 - Erosive pustular dermatosis 233
MANAGEMENT STRATEGY 233
71 - Erythema annulare centrifugum 235
MANAGEMENT STRATEGY 235
72 - Erythema dyschromicum perstans 238
MANAGEMENT STRATEGY 238
THERAPY 238
73 - Erythema elevatum diutinum 239
MANAGEMENT STRATEGY 239
74 - Erythema multiforme 242
MANAGEMENT STRATEGY 242
75 - Erythema nodosum 245
MANAGEMENT STRATEGIES 245
76 - Erythrasma 248
MANAGEMENT STRATEGY 248
77 - Erythroderma 250
MANAGEMENT STRATEGY 250
78 - Erythrokeratodermas 255
MANAGEMENT STRATEGY 255
79 - Erythromelalgia 258
MANAGEMENT STRATEGY 258
80 - Erythropoietic protoporphyria 261
MANAGEMENT STRATEGY 261
81 - Extramammary Paget disease 265
MANAGEMENT STRATEGY 265
82 - Fabry disease 268
MANAGEMENT STRATEGY 268
83 - Flushing 272
MANAGEMENT STRATEGY 272
84 - Follicular mucinosis 275
MANAGEMENT STRATEGY 275
85 - Folliculitis 278
MANAGEMENT STRATEGY 278
86 - Folliculitis decalvans 281
MANAGEMENT STRATEGY 281
87 - Fox–Fordyce disease 284
MANAGEMENT STRATEGY 284
88 - Furunculosis 286
MANAGEMENT STRATEGY 286
89 - Condyloma acuminata 288
MANAGEMENT STRATEGY 288
90 - Geographic tongue 291
MANAGEMENT STRATEGY 291
91 - Gianotti–Crosti syndrome 293
MANAGEMENT STRATEGY 293
92 - Gonorrhea 295
MANAGEMENT STRATEGY 295
SPECIAL CONSIDERATIONS 297
93 - Graft-versus-host disease 298
MANAGEMENT STRATEGY 298
ACUTE GVHD 298
CHRONIC GVHD 300
94 - Granuloma annulare 302
MANAGEMENT STRATEGY 302
LOCALIZED GRANULOMA ANNULARE 302
GENERALIZED (DISSEMINATED) GRANULOMA ANNULARE 304
95 - Granuloma faciale 307
MANAGEMENT STRATEGY 307
Acknowledgments 308
96 - Granuloma inguinale 309
MANAGEMENT STRATEGY 309
SPECIAL CONSIDERATIONS 310
97 - Granulomatous cheilitis 312
MANAGEMENT STRATEGY 312
98 - Hailey–Hailey disease 316
MANAGEMENT STRATEGY 316
99 - Hand and foot eczema (endogenous, dyshidrotic eczema, pompholyx) 319
MANAGEMENT STRATEGY 319
100 - Hemangiomas 322
MANAGEMENT STRATEGY 322
101 - Hereditary angioedema 325
MANAGEMENT STRATEGY 325
ACUTE ANGIOEDEMA 325
Long-Term Prophylaxis 325
ACUTE ANGIOEDEMA 326
LONG-TERM PROPHYLAXIS OF HEREDITARY ANGIOEDEMA 327
PREVENTION OF RELAPSE DUE TO DENTAL AND SURGICAL INTERVENTIONS 328
TREATMENT IN CHILDREN 328
HEREDITARY ANGIOEDEMA WITHNORMAL C1INH 328
102 - Hereditary hemorrhagic telangiectasia 329
MANAGEMENT STRATEGY 329
103 - Herpes genitalis 333
MANAGEMENT STRATEGY 333
Primary Genital Infection 334
Acute Reactivation Episodes 334
Prophylactic Treatment 334
NOVEL AND OTHER THERAPIES 335
PREVENTION 336
104 - Herpes labialis 337
MANAGEMENT STRATEGY 337
OTHER THERAPIES 339
105 - Herpes zoster 340
MANAGEMENT STRATEGY 340
106 - Hidradenitis suppurativa 344
MANAGEMENT STRATEGY 344
SPECIFIC INVESTIGATION 345
107 - Histoplasmosis 347
MANAGEMENT STRATEGY 347
108 - Hydroa vacciniforme 351
MANAGEMENT STRATEGY 351
109 - Hyperhidrosis 354
MANAGEMENT STRATEGY 354
110 - Hypertrichosis and hirsutism 358
INTRODUCTION 358
MANAGEMENT STRATEGY 358
111 - Hypopigmented disorders 362
Postinflammatary Hypomelanosis 362
Pityriasis Alba 362
Pityriasis Versicolor 362
Leprosy (Hansen Disease) 362
Hypopigmented Variants of Common Dermatosis 362
Idiopathic Guttate Hypomelanosis 363
Progressive Macular Hypomelanosis 363
Chemical Leukoderma 363
MANAGEMENT STRATEGY 363
112 - Ichthyoses 365
MANAGEMENT STRATEGY 365
113 - Impetigo 369
MANAGEMENT STRATEGY 369
114 - Inducible urticarias, aquagenic pruritus, and cholinergic pruritus 372
Inducible urticarias 372
MANAGEMENT STRATEGY 372
Pharmacologic 372
Nonpharmacologic 372
AQUAGENIC PRURITUS 376
MANAGEMENT STRATEGY 376
CHOLINERGIC PRURITUS 377
MANAGEMENT STRATEGY 377
115 - Irritant contact dermatitis 378
MANAGEMENT STRATEGY 378
116 - Jellyfish stings 381
CLINICAL FEATURES 381
Major box jellyfish (Chironex fleckeri) 381
Irukandji jellyfish (Carukia barnesi) 381
Bluebottles or Portuguese man-of-war (Physalia species) 381
True jellyfish (Schyphozoans) 381
Corals and sea anemones (Anthozoans) 381
Seabather’s eruption 381
CUTANEOUS MANIFESTATIONS OF JELLYFISH STINGS 382
MANAGEMENT STRATEGY 382
117 - Jessner lymphocytic infiltrate 384
MANAGEMENT STRATEGY 384
118 - Juvenile plantar dermatosis 386
MANAGEMENT STRATEGY 386
119 - Juvenile xanthogranuloma 388
MANAGEMENT STRATEGY 388
Eye involvement 388
Systemic JXG 388
Triple association of JXG, NF-1, and JMML 388
Association of JXG and hematologic malignancy in adults 389
120 - Kaposi sarcoma 391
MANAGEMENT STRATEGY 391
121 - Kawasaki disease 395
MANAGEMENT STRATEGIES 395
122 - Keloids 398
MANAGEMENT STRATEGY 398
123 - Keratoacanthoma 402
MANAGEMENT STRATEGY 402
124 - Keratosis pilaris and variants 405
MANAGEMENT STRATEGY 405
125 - Langerhans cell histiocytosis 409
MANAGEMENT STRATEGY 409
126 - Leg ulcers 414
MANAGEMENT STRATEGY 414
Wound care 414
Dressing 414
Venous leg ulcers 414
Arterial ulcers 414
Diabetic neuropathy 414
Pressure ulcers 414
127 - Leiomyoma 416
MANAGEMENT STRATEGY 416
128 - Leishmaniasis 418
MANAGEMENT STRATEGY 418
129 - Lentigo maligna 422
MANAGEMENT STRATEGY 422
130 - Leprosy (including reactions) 426
MANAGEMENT STRATEGY 426
131 - Leukocytoclastic vasculitis 429
MANAGEMENT STRATEGY 429
132 - Lichen myxedematosus 433
MANAGEMENT STRATEGY 433
133 - Lichen nitidus 436
MANAGEMENT STRATEGY 436
134 - Lichen planopilaris 438
MANAGEMENT STRATEGY 438
135 - Lichen planus 441
MANAGEMENT STRATEGY 441
136 - Lichen sclerosus 445
MANAGEMENT STRATEGY 445
137 - Lichen simplex chronicus 448
MANAGEMENT STRATEGY 448
138 - Linear IgA bullous dermatosis 451
MANAGEMENT STRATEGY 451
139 - Lipodermatosclerosis 454
MANAGEMENT STRATEGY 454
140 - Livedo reticularis 457
MANAGEMENT STRATEGY 457
141 - Livedoid vasculopathy 460
MANAGEMENT STRATEGY 460
142 - Lyme borreliosis 464
MANAGEMENT STRATEGY 464
Early localized Lyme disease 464
Early disseminated Lyme disease 464
Late Lyme disease 465
Posttreatment symptoms 465
Reinfection and vaccination 465
SPECIFIC INVESTIGATIONS 465
Testing 465
Prevention 465
Prophylaxis 465
Treatment 465
143 - Lymphangioma circumscriptum 467
MANAGEMENT STRATEGIES 467
144 - Lymphedema 470
MANAGEMENT STRATEGIES 470
145 - Lymphocytoma cutis 472
MANAGEMENT STRATEGY 472
146 - Lymphogranuloma venereum 475
MANAGEMENT STRATEGY 475
147 - Lymphomatoid papulosis 477
MANAGEMENT STRATEGY 477
148 - Malignant atrophic papulosis 481
MANAGEMENT STRATEGY 481
149 - Malignant melanoma 484
MANAGEMENT STRATEGY 484
150 - Mastocytoses 489
MANAGEMENT STRATEGY 489
151 - Melasma 493
MANAGEMENT STRATEGY 493
152 - Merkel cell carcinoma 496
MANAGEMENT STRATEGY 496
153 - Methicillin-resistant Staphylococcus aureus and Panton–Valentine leukocidin Staphylococcus aureus infections 499
MANAGEMENT STRATEGY (MRSA) 499
SPECIFIC INVESTIGATIONS 499
Epidemiology 500
Prognosis 500
Pathogenesis 500
154 - Miliaria 505
MANAGEMENT STRATEGY 505
155 - Molluscum contagiosum 508
MANAGEMENT STRATEGY 508
156 - Morphea 512
MANAGEMENT STRATEGY 512
157 - Mucoceles 515
MANAGEMENT STRATEGY 515
158 - Mucous membrane pemphigoid 517
MANAGEMENT STRATEGY 517
Mild disease 517
Treatment-resistant or severe disease 517
159 - Mycetoma: eumycetoma and actinomycetoma 522
MANAGEMENT STRATEGY 522
160 - Mycobacterial (atypical) skin infections 526
FISH TANK (SWIMMING POOL) GRANULOMA 526
MANAGEMENT STRATEGY 526
MYCOBACTERIUM ULCERANS 528
MANAGEMENT STRATEGY 528
MYCOBACTERIUM KANSASII 529
161 - Mycosis fungoides and SĂ©zary syndrome 532
MANAGEMENT STRATEGY 532
162 - Myiasis 538
MANAGEMENT STRATEGY 538
163 - Myxoid cyst 541
MANAGEMENT STRATEGY 541
164 - Nail psoriasis 543
MANAGEMENT STRATEGY 543
165 - Necrobiosis lipoidica 548
MANAGEMENT STRATEGY 548
166 - Necrolytic acral erythema 552
MANAGEMENT STRATEGY 552
167 - Necrolytic migratory erythema 554
MANAGEMENT STRATEGY 554
168 - Nephrogenic systemic fibrosis 557
MANAGEMENT STRATEGY 557
169 - Neurofibromatosis, type 1 559
MANAGEMENT STRATEGY 559
170 - Nevoid basal cell carcinoma syndrome 562
MANAGEMENT STRATEGY 562
171 - Nevus sebaceus 567
MANAGEMENT STRATEGY 567
172 - Notalgia paresthetica 569
MANAGEMENT STRATEGY 569
173 - Onchocerciasis 571
MANAGEMENT STRATEGY 571
Treatment of Individuals Outside of Endemic Areas 571
Treatment of Individuals Within Endemic Areas 571
Mass Treatment Programs 571
OTHER THERAPIES 573
174 - Oral lichen planus 574
MANAGEMENT STRATEGY 574
175 - Orf 577
MANAGEMENT STRATEGY 577
176 - Palmoplantar keratoderma 579
MANAGEMENT STRATEGY 579
177 - Palmoplantar pustulosis 582
MANAGEMENT STRATEGY 582
178 - Panniculitis 584
MANAGEMENT STRATEGY 584
LUPUS PANNICULITIS 586
NODULAR VASCULITIS 587
PANCREATIC PANNICULITIS 587
CYTOPHAGIC HISTIOCYTIC PANNICULITIS 588
Α1-ANTITRYPSIN DEFICIENCY PANNICULITIS 589
179 - Papular urticaria 590
MANAGEMENT STRATEGY 590
180 - Paracoccidioidomycosis (South American blastomycosis) 593
MANAGEMENT STRATEGY 593
181 - Parapsoriasis 597
MANAGEMENT STRATEGY 597
SMALL PLAQUE PARAPSORIASIS 597
LARGE PLAQUE PARAPSORIASIS 598
182 - Paronychia 600
MANAGEMENT STRATEGY 600
183 - Parvovirus infection 603
MANAGEMENT STRATEGY 603
184 - Pediculosis 606
PEDICULOSIS CAPITIS 606
MANAGEMENT STRATEGY 606
PEDICULOSIS CORPORIS 609
185 - Pemphigus 611
MANAGEMENT STRATEGY 611
186 - Perforating dermatoses 616
MANAGEMENT STRATEGY 616
Acknowledgment 618
187 - Perioral dermatitis 619
MANAGEMENT STRATEGY 619
188 - Peutz–Jeghers syndrome 621
MANAGEMENT STRATEGY 621
189 - Pinta and yaws 624
MANAGEMENT STRATEGY 624
190 - Pitted and ringed keratolysis (keratolysis plantare sulcatum) 626
MANAGEMENT STRATEGY 626
191 - Pityriasis rubra pilaris 629
MANAGEMENT STRATEGY 629
192 - Pityriasis lichenoides chronica 632
MANAGEMENT STRATEGY 632
193 - Pityriasis lichenoides et varioliformis acuta 635
MANAGEMENT STRATEGY 635
194 - Pityriasis rosea 638
MANAGEMENT STRATEGY 638
195 - Polycystic ovary syndrome 640
MANAGEMENT STRATEGY 640
196 - Polymorphic light eruption 643
MANAGEMENT STRATEGY 643
197 - Porokeratoses 646
MANAGEMENT STRATEGY 646
198 - Porphyria cutanea tarda 650
MANAGEMENT STRATEGY 650
199 - Port wine stain (“nevus flammeus”) 653
MANAGEMENT STRATEGY 653
200 - Postinflammatory hyperpigmentation and other disorders of hyperpigmentation 658
POSTINFLAMMATORY HYPERPIGMENTATION 658
FRECKLES 658
LENTIGINES 658
MELASMA 658
PERIORBITAL HYPERPIGMENTATION 659
RIEHL MELANOSIS 659
PHOTOTOXIC DERMATITIS 659
ERYTHEMA DYSCHROMICUM PERSTANS 659
LICHEN PLANUS PIGMENTOSUS 659
POIKIODERMA OF CIVATTE 659
MANAGEMENT STRATEGY 659
201 - Pregnancy dermatoses 662
POLYMORPHIC ERUPTION OF PREGNANCY 662
MANAGEMENT STRATEGY 662
PEMPHIGOID GESTATIONIS 663
MANAGEMENT STRATEGY 663
INTRAHEPATIC CHOLESTASIS OF PREGNANCY 665
MANAGEMENT STRATEGY 665
ATOPIC ERUPTION OF PREGNANCY 666
MANAGEMENT STRATEGY 667
202 - Pretibial myxedema 668
MANAGEMENT STRATEGY 668
203 - Prurigo nodularis 672
MANAGEMENT STRATEGY 672
204 - Prurigo pigmentosa 676
MANAGEMENT STRATEGY 676
205 - Pruritus 678
MANAGEMENT STRATEGY 678
NEUROPATHIC ITCH 679
CHOLESTATIC ITCH 680
ITCH ASSOCIATED WITH CHOLESTASIS OF PREGNANCY 681
RENAL ITCH 682
ITCH ASSOCIATED WITH MALIGNANCY 684
ITCH ASSOCIATED WITH HEMATOLOGIC DISORDERS 684
MISCELLANEOUS DISEASES ASSOCIATED WITH ITCH 685
206 - Pruritus ani 686
MANAGEMENT STRATEGY 686
207 - Pruritus vulvae 688
MANAGEMENT STRATEGY 688
208 - Pseudofolliculitis barbae 691
MANAGEMENT STRATEGY 691
209 - Pseudoxanthoma elasticum 695
MANAGEMENT STRATEGY 695
Acknowledgment 696
210 - Psoriasis 697
MANAGEMENT STRATEGY 697
GUTTATE PSORIASIS 698
INVERSE PSORIASIS 698
IMPETIGO HERPETIFORMIS 698
ERYTHRODERMIC PSORIASIS 705
PUSTULAR PSORIASIS 706
211 - Psychogenic excoriation 708
MANAGEMENT STRATEGY 708
212 - Pyoderma gangrenosum 711
MANAGEMENT STRATEGY 711
213 - Pyogenic granuloma 716
MANAGEMENT STRATEGY 716
214 - Radiation dermatitis 719
MANAGEMENT STRATEGY 719
215 - Raynaud disease and phenomenon 722
MANAGEMENT STRATEGY 722
216 - Reactive arthritis 726
MANAGEMENT STRATEGY 726
Antibiotics 729
217 - Regional pain and complex regional pain 730
COMPLEX REGIONAL PAIN SYNDROME 730
MANAGEMENT STRATEGY 730
PREVENTION 731
218 - Relapsing polychondritis 733
MANAGEMENT STRATEGY 734
219 - Rhinophyma 737
MANAGEMENT STRATEGY 737
220 - Rocky Mountain spotted fever and other rickettsial infections 739
RICKETTSIAL SPOTTED FEVERS 739
MANAGEMENT STRATEGY 739
TYPHUS GROUP 741
Epidemic typhus 741
Murine typhus 741
Scrub typhus 741
MANAGEMENT STRATEGY 741
RICKETTSIALPOX 742
221 - Rosacea 744
MANAGEMENT STRATEGY 744
INFLAMMATORY ROSACEA 744
ERYTHEMATOTELANGIECTATIC ROSACEA 748
ROSACEA FLUSHING 749
ROSACEA LYMPHEDEMA (MORBIHAN DISEASE) 750
OCULAR ROSACEA 750
ROSACEA FULMINANS 751
222 - Sarcoidosis 752
MANAGEMENT STRATEGY 752
223 - Scabies 757
MANAGEMENT STRATEGY 757
224 - Scleredema 761
MANAGEMENT STRATEGY 761
225 - Scleroderma 764
MANAGEMENT STRATEGY 764
OTHER: INTERNAL ORGAN INVOLVEMENT 767
226 - Sebaceous hyperplasia 769
MANAGEMENT STRATEGY 769
227 - Seborrheic eczema 771
MANAGEMENT STRATEGY 771
NONSCALP DISEASE 771
SCALP DISEASE 773
228 - Seborrheic keratosis 775
MANAGEMENT STRATEGY 775
Seborrheic Keratosis Variants 775
Multiple Seborrheic Keratoses 775
229 - Sporotrichosis 777
MANAGEMENT STRATEGY 777
GUIDELINES 779
230 - Squamous cell carcinoma 780
MANAGEMENT STRATEGY 780
231 - Staphylococcal scalded skin syndrome 785
MANAGEMENT STRATEGY 785
232 - Steatocystoma multiplex 788
MANAGEMENT STRATEGY 788
233 - Stoma care 790
MANAGEMENT STRATEGY 790
234 - Striae 794
MANAGEMENT STRATEGY 794
235 - Subacute cutaneous lupus erythematosus 797
MANAGEMENT STRATEGY 797
236 - Subcorneal pustular dermatosis 802
MANAGEMENT STRATEGY 802
237 - Subcutaneous fat necrosis of the newborn 805
MANAGEMENT STRATEGY 805
238 - Sweet syndrome 807
MANAGEMENT STRATEGY 807
239 - Syphilis 810
MANAGEMENT STRATEGY 810
Incubation Period 810
Primary Syphilis 810
Secondary Syphilis 810
Neurologic Syphilis 811
Latent Syphilis 811
Tertiary Syphilis 811
DIAGNOSTICS AND TREATMENT 811
240 - Syringomata 814
MANAGEMENT STRATEGY 814
241 - Tinea capitis 816
MANAGEMENT STRATEGY 816
242 - Tinea pedis and skin dermatophytosis 820
MANAGEMENT STRATEGY 820
243 - Tinea unguium 823
MANAGEMENT STRATEGY 823
244 - Tinea versicolor (pityriasis versicolor) 827
MANAGEMENT STRATEGY 827
245 - Toxic epidermal necrolysis and Stevens–Johnson syndrome 830
MANAGEMENT STRATEGY 830
246 - Transient acantholytic dermatosis (Grover disease) 834
MANAGEMENT STRATEGY 834
247 - Trichotillomania 836
DIAGNOSIS 836
MANAGEMENT STRATEGY 836
248 - Tuberculosis and tuberculids 838
MANAGEMENT STRATEGY 838
249 - Urticaria and angioedema 840
URTICARIA 840
INTRODUCTION 840
MANAGEMENT STRATEGY 840
Acute urticaria 841
Chronic spontaneous urticaria 841
Chronic inducible urticaria 842
ANGIOEDEMA 842
INTRODUCTION 842
MANAGEMENT STRATEGY FOR BRADYKININ-MEDIATED ANGIOEDEMA 843
250 - Varicella 844
MANAGEMENT STRATEGY 844
PREGNANCY 845
PROPHYLAXIS 846
251 - Viral exanthems: rubella, roseola, rubeola, and enteroviruses 848
RUBELLA 848
MANAGEMENT STRATEGY 848
ROSEOLA 849
252 - Viral warts 852
MANAGEMENT STRATEGY 852
Immunologic Therapy 854
Destructive Therapies 855
Virucidal Treatments 856
Antiproliferative Agents 857
Complementary and Alternative Therapies 858
253 - Vitiligo 859
MANAGEMENT STRATEGY 859
Segmental Vitiligo and Limited Vitiligo 859
Widespread Disease (>3% BSA) 859
Maintenance Therapy 860
Emerging Treatments 860
Emerging Treatments 863
254 - Vulvodynia 864
MANAGEMENT STRATEGY 864
255 - Wells syndrome 868
MANAGEMENT STRATEGY 868
256 - Xanthomas 870
MANAGEMENT STRATEGY 870
257 - Xeroderma pigmentosum 873
MANAGEMENT STRATEGY 873
Acknowledgment 877
258 - Xerosis 878
MANAGEMENT STRATEGY 878
259 - Yellow nail syndrome 881
MANAGEMENT STRATEGY 881
Index 883
A 883
B 887
C 888
D 893
E 895
F 897
G 899
H 899
I 901
J 904
K 904
L 904
M 906
N 908
O 910
P 910
Q 915
R 915
S 916
T 919
U 922
V 922
W 923
X 923
Y 923
Z 923

Contact Us

123Doc Education 45 Stanlake Road 9 London, W12 7HG T: +44 (0)203 0313 866

Quick Navigation

2025 123Library

Powered by CloudPublish

We use cookies to ensure that you get the best experience on our website. Learn more about how we use cookies.